Abstract: A liner for use with a basin to contain a liquid features two bodies of flexible plastic which are joined at adjacent faces of the distinct plastic bodies so as to form an interface of the plastic bodies. The liner includes an air conduit adapted for guiding pressurized air substantially within the thickness of the bag from an air discharge apparatus, which generates the pressurized air, to the interior of the liner. A length of the air conduit is formed at the interface of the plastic bodies such that a circumferential wall of the length of the air conduit is defined in part by an inner face of each plastic body. The plastic body of the liner that is arranged to contact an inside face of the basin is substantially imperforate so as to isolate the liner interior, where the liquid is received, from the basin.

Abstract: A method comprises generating, by an implantable stimulator, stimulation sessions at a duty cycle that is less than 0.05 and applying, by the implantable stimulator in accordance with the duty cycle, the stimulation sessions to a patient. The duty cycle is a ratio of T3 to T4. Each stimulation session included in the stimulation sessions has a duration of T3 minutes and occurs at a rate of once every T4 minutes. The implantable stimulator is powered by a primary battery located within the implantable stimulator and having an internal impedance greater than 5 ohms.

Abstract: Methods and systems for a drug supply with an associated dosing regimen are described. Sachets may to store at least one pharmaceutical drug. A dosing bag holds at least one sachet and stores a specific pharmaceutical dose. Dosing bag assemblies are formed from one or more than one dosing bag and can be connected together to form a package. A book may be formed to include a plurality of drug containing bags or bag assemblies, which may form pages in the booklet. The dosing bags may be removed from the pages to allow the patient to take the specific pharmaceutical dose with them. alternatively, the dosing bag may be opened in the booklet and the specific pharmaceutical dose may be taken.

Abstract: A container for storing consumer products is described. The container includes a tray having a generally planar top surface into which has been formed one or more discrete cavities. A seal includes a cover film secured to the top surface of the tray to seal the one or more cavities. The cover film has pre-formed lines of separation defining a releasable portion per cavity, and a barrier patch per releasable portion secured to the cover film. Each releasable portion is attached to the remainder of the cover film by a bridge region defined by a gap in the associated pre-formed line of separation. Each barrier patch includes a main portion that is shaped and sized so that in use it overlies an associated cavity, and a securing portion that projects outwardly from the main portion and which is substantially aligned with the bridge region of the associated releasable portion.

Abstract: A crushing device (100) includes a base (101). A first sidewall (103) and a second sidewall (104) extend distally from the base. A crushing assembly (102) is coupled between the first sidewall and the second sidewall. The crushing assembly can include a first crushing plate (601) pivotally coupled about a first pivot (406) defining a first axis (111) and a second crushing plate (602) pivotally coupled about a second pivot (507) defining a second axis (112). A lever (110) is coupled to the first crushing plate, and is selectively movable between a first position (600) and a second position (700) to rotate the first crushing plate in a first radial direction (703). A cog insert (604), coupled between the first crushing plate and the second crushing plate, causes the second crushing plate to rotate in a second radial direction (704), opposite the first radial direction.

Abstract: A pill dispensing apparatus for use to dispense a pill from a blister package includes a base assembly having an interior cavity formed by an upper plate coupled to a lower housing, the upper plate having an opening and partially extending over the lower housing to form a spout in the lower housing, an arm pivotably mounted to the base assembly and having a post protruding downward toward the base assembly, and a spring coupled to the arm and upper plate of the base assembly. The apparatus is designed to receive the blister package between the base assembly and arm. Pivotal movement of the arm toward the base assembly allows the post of the arm to push the pill in the blister package through the opening in the upper plate of the base assembly. This allows the pill to travel in the base assembly's internal cavity and out the spout.

Abstract: A portable pill dispenser is disclosed herein. The portable pill dispenser includes a container configured to house at least one pill therein. The container is attachable to a housing, which comprises a dispensing opening. A dispensing mechanism, a ramp, and a control panel are disposed within the housing. The dispensing mechanism is configured to dispense the at least one pill from the container to the dispensing opening. The ramp is configured to direct the at least one pill to the dispensing mechanism. A verification mechanism is disposed about the housing. The verification mechanism is configured to activate the dispensing mechanism. The control panel is in electrical communication with the dispensing mechanism and the verification mechanism.

Abstract: The present invention is disclosing a secure medication dispenser. Secure medication dispenser comprises a housing. Housing comprise a timer configured to set time to release a specified dosage of each of a plurality of medications. Housing further comprises an environment control system configured to control one or more physical environmental characteristic for said plurality of medications inside said housing to preserve corresponding potencies. Housing further comprises a plurality of authorization mechanisms configured to lock and seal said plurality of medications inside said housing. Housing further comprises an electronic dispensing system configured to dispense, at a time, a single medication from corresponding plurality of medications to a user upon receiving an ejection command and successful authorization of said user by the plurality of authorization mechanisms.

Abstract: Refill and dosage management devices and associated systems and methods for use with computerized oral prescription administration (COPA) devices are provided. In one embodiment, an apparatus includes a housing having a structure sized and shaped to receive at least a portion of a mouthpiece of an intended user; and a dispensing unit coupled to the housing, the dispensing unit configured to dispense a substance into a reservoir of the mouthpiece. In another embodiment, a method includes receiving, by a docking station, at least a portion of a mouthpiece of an intended user; and dispensing, by a dispensing unit coupled to the docking station, a substance into a reservoir of the mouthpiece.

Abstract: A container gripping aid (1) has a jacket (2) for reception of a container such as a baby bottle (3). The jacket (2) has a mesh configuration with a plurality of through-holes (5) to facilitate gripping of the jacket (2) by a baby. The jacket (2) has an egg-like shape. Thus, when it is engaged with the bottle (3), most of the jacket (2) side wall is supported spaced-apart from an exterior side wall (6) of the container (3) which enables a baby to easily grip the mesh of the jacket (2).

Abstract: The invention relates to a kit of parts for preparing a glass ionomer composition for dental use, the kit of parts comprising a Powder Part P and a Liquid Part L, Powder Part P comprising: acid-reactive inorganic filler, Liquid Part L comprising: water, complexing agent, polyacid, either the Powder Part P or the Liquid Part L or the Powder Part P and the Liquid Part L comprising non-aggregated nano-sized particles based on silica or alumina, the composition obtained by combining the components of Powder Part P and Liquid Part L before hardening comprising the components in the following amounts: non-aggregated nano-sized particles: from 0.1 to 15 wt.-%, acid-reactive filler in an amount from 50 to 75 wt.-%, polyacid: 7 to 20 wt.-%, complexing agent: 0.5 to 3 wt.-%, water: 5 to 18 wt.-%, wt.-% with respect to the weight of the whole composition.

Abstract: Apertured fibrous structures and more particularly apertured fibrous structures containing one or more fibrous elements, for example filaments, containing one or more fibrous element-forming materials and one or more active agents that are releasable from the fibrous element when exposed to conditions of intended use, and methods for making same.

Abstract: Cosmetic peeling cream, comprising a) an oil-in-water emulsion, containing (i) at least one fatty substance, (ii) at least one C12-C24 fatty alcohol, (iii) at least one co-emulsifier, and (iv) at least one thickening agent; b) a peeling agent, wherein the constituents a) and b) are present in a total ratio of a) to b) of from about 9:1 to about 1:1. Also provided are the use of the peeling cream, the method and application of said cream, as well as the method for the production thereof.

Abstract: The present disclosure provides low water dentifrice compositions comprising an effective amount of a zinc ion source, a stannous ion source, a polyphosphate and an acid in a calcium pyrophosphate base. The acid lowers the pH of the composition to enable stabilization of the metal ions and extend shelf-life of the composition.

Abstract: Antifibrinolytic agents are administered to a human individual to treat fine lines, wrinkles and overall skin tone of the face and body, as well as inflammation and tissue degradation effects.

Abstract: Methods, formulations, and kits for curling and/or preventing damage in the curling of hair are disclosed herein. Hair can be curled by treatment with hydroxide-containing agents, in combination with one or more active agents, without the need for thiol-based or peroxide-based agents. The active agent can be applied simultaneously with the hydroxide-containing agent, to impart curl to the hair. They may be applied as a combined formulation or as separate formulations applied simultaneously. Use of the active agent along with a hydroxide-containing agent can be used to control the level of curl imparted to hair, as compared to the natural amount of curl, if any, in the untreated hair.

Abstract: The present invention relates to an in particular cosmetic or dermatological compositions comprising, in a physiologically acceptable support: • a) at least one merocyanine of formula (1) or (2) (1), (2) • b) at least one oily phase comprising at least one polyalkylene glycol of formula (4): (4) and to their use for caring for and/or making up a keratin material.

Abstract: The present invention relates to a transparent oily solid cosmetic having excellent transparency, no bleeding, and excellent usability. [Problem] It has been difficult to produce an oily solid cosmetic having both excellent transparency and low bleeding by merely combining conventional materials. [Solution] A transparent oily solid cosmetic comprising a transparent gelling agent, an oil agent having a refractive index of 1,460 or more at 20° C., and an oil agent having an expansion coefficient of 0.065%/° C. or less. In particular, a transparent oily solid cosmetic wherein the transparent gelling agent comprises dibutyl lauroyl glutamide and/or dibutyl ethylhexanoyl glutamide.

Abstract: Disclosed herein are dentifrices comprising a zinc amino acid halide, which provide a precipitate of zinc oxide upon use with dilution with water and/or saliva. Methods of making and using the dentifrices are also provided.

Abstract: An aqueous surfactant composition comprising one or more alpha-sulfo fatty acid disalts (A) of the general formula (I), R1CH(SO3M1)COOM2??(I), wherein the radical R1 is a linear or branched alkyl or alkenyl radical with 6 to 18 carbon atoms and the radicals M1 and M2, independently of one another, are selected from the group H, Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine, one or more amidoalkylbetaines (B) of the general formula (II), R2—CO—NH—(CH2)y—N+(CH3)2—CH2—COO???(II) in which the radical R2 is a linear or branched alkyl or alkenyl radical with 7 to 19 carbon atoms and the index y is an integer in the range 2 to 4, and water, where specific limiting conditions are to be observed. The compositions are transparent, storage-stable, characterized by good foaming ability and good viscosity, and are suitable for cosmetic products and also detergents and cleaners.

Abstract: The present invention relates to a cosmetic composition using a mannosylerythritol lipid, which is a kind of glycolipid, as a stabilizer in order to prevent kojyl methylenedioxycinnamate, which is an active ingredient having various skin effects such as antiaging, whitening and antioxidation, from causing crystallization inside a dosage form. Even if the cosmetic composition according to the present invention contains a high concentration of an active ingredient, crystal precipitation does not occur in various dosage forms, and thus the functionality of the active ingredient is maximized, skin delivery is increased and the texture during use is improved.

Abstract: The invention provides white keratin protein compositions and methods of making and using white keratin protein compositions.

Abstract: This invention discloses a novel class of skincare products to remove iron in the skin and its preparation method. The core active components, termed as de-ironizing inducers (DII), consist of a reducing agent and a precipitating agent. The reducing agent is selected from vitamin C, vitamin E, glutathione, vitamin A, vitamin D and their derivatives. The precipitating agent is chosen from calcium carbonate, pearl powder, magnesium carbonate, barium carbonate, calcium phosphate, magnesium phosphate, barium phosphate, calcium silicate, magnesium silicate, and barium silicate. Molar ratios of the reducing agent with the precipitating agent range from 1:3-6 and the core components in the skin care product range from 5% to 10% w/w. The PH value of the skincare product is between 6.6 and 7.4. The skin care products can safely and effectively remove iron in the skin, which has been shown to accelerate skin's natural aging and photoaging.

Abstract: The invention relates to a cosmetic process for treating keratin materials, comprising: either the sequential application to the keratin materials of a composition comprising a maleic anhydride ethylenic polymer and of an amine compound chosen from polyamine compounds bearing several primary amine and/or secondary amine groups and amino alkoxysilanes, or the topical application to the keratin materials of a composition derived from the mixing of a composition comprising a maleic anhydride acrylic polymer and of an amine compound chosen from amino alkoxysilanes; the ethylenic polymer being derived from the polymerization of: (a) 45% to 95% by weight, relative to the total weight of monomers, of an ethylenic monomer bearing an at least C8 linear or branched alkyl group; (b) 5% to 25% by weight of maleic anhydride; (c) 0 to 50% by weight of additional monomer; the compositions used being anhydrous when the amine compound is an amino alkoxysilane.

Abstract: A method for reducing skin sagging and/or improving skin brightness is provided. The method comprises administering to a subject in need an effective amount of gum tragacanth composition, wherein the gum tragacanth composition comprises gum tragacanth and a pharmaceutically acceptable carrier and is topically administered to the skin at least once a day to achieve the effects of maintaining skin tightness and moisture and improving skin brightness.

Abstract: This invention relates generally to compositions comprising honey and glycerine, methods for preparing such compositions and their use for the treatment or prevention of skin diseases such as acne, rosacea, nappy rash, or those caused by herpes simplex virus 1 or herpes simplex virus 2.

Abstract: Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanoparticles, and polymeric microparticles or nanoparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.

Abstract: An antimicrobial polymer for use in an ophthalmic implant, includes at least one antimicrobial monomer; and at least one other monomer selected from an acrylic, silicone, vinyl and collagen monomer.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Formulations for oral transmucosal compositions that include aromatase inhibitors (AIs) in combination with transmucosal absorption enhancers are disclosed. Disclosed oral transmucosal compositions may be for immediate release or slow release, and may be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Disclosed oral transmucosal compositions may include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms may include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms may be: mucoadhesive liquids such as gel-forming liquid; gel-forming; semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of AIs. Disclosed oral transmucosal compositions may allow the delivery of AIs directly into the patient's bloodstream, thus providing high bioavailability of AIs; therefore, required dose may be lower.

Abstract: An aqueous suspension preparation that comprises a macrolide antibacterial agent as an active component. The aqueous suspension preparation is characterized by comprising nanoparticles of a macrolide antibacterial agent and a dispersion stabilizer; an aqueous suspension in which the average particle size of nanoparticles is 500 nm or less and the D90 particle size is 1,500 nm or less; a parenterally administered pharmaceutical composition that comprises this aqueous suspension preparation; an injection preparation; and eye drops or ear drops, more specifically, eye drops for the treatment or prevention of inflammatory diseases of the eye or ear drops for the treatment or prevention of inflammatory diseases of the ear.

Abstract: A pharmaceutical composition of high drug loading comprising an active pharmaceutical ingredient (API) and pharmaceutical acceptable additives, which include glass-solution forming additive and/or eutectic-mixture forming additive, is provided. The composition is dispersed uniformly to form a hybrid solid dispersion consisting of crystalline-suspension, glass-solution and/or eutectic-mixture, where the crystalline API is uniformly distributed in the hybrid solid dispersion and exists in nano/micro particle size range. The amorphous API, when present, is uniformly distributed in the hybrid solid dispersion. The API may exist in different chemical and/or physical forms. The API is present in an amount of from more than about 50% wt/wt to about 90% wt/wt with respect to the total amount of the active pharmaceutical ingredient and the pharmaceutically acceptable glass-solution forming and/or eutectic-mixture forming additives.

Abstract: The present invention relates to methods of forming miniemulsions and use of the miniemulsions as a delivery system for bioactive agents. In particular, the present invention relates to methods for forming a miniemulsion comprising providing a first phase comprising a hydrophilic surfactant, lipophillic surfactant and water and a second phase comprising a lipid, wherein said miniemulsion comprises emulsified particles having a mean diameter of 1 ?m or less.

Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.

Abstract: The invention disclosed herein is a highly concentrated powdered oleoresin composition comprises oleoresin(s), Mineral hydroxide(s)/oxide(s)/chloride(s)/carbonate(s) and optionally comprises organic/inorganic acid(s); wherein said composition has enhanced stability and increased bioavailability. The invention also disclosed herein a process for preparation of said composition.

Abstract: Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

Abstract: The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.

Abstract: The present invention provides a method for preparing a reconstituted apolipoprotein B lipoparticle and the method comprises steps of (a) dissolving an apolipoprotein B and a lipid in a first buffer containing 2 M to 8 M urea and 1 wt % to 15 wt % amphiphilic compounds to form a mixture; and (b) dialyzing the mixture against a second buffer containing 0 M to 2M urea and 0 wt % to 0.5 wt % amphiphilic compounds for 1 to several times for lowering concentrations of the urea and the amphiphilic compounds in the mixture. The present invention further provides an apolipoprotein B lipoparticle and a use for the production of an apolipoprotein B lipoparticle used for delivering a hydrophobic substance.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: The present invention relates to pharmaceutical compositions comprising safinamide, and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands.

Abstract: ?-hydroxy butyric acid in combination with ?-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/L), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of ?-hydroxy butyric acid and salt results in substantial improvements in metabolic bookmakers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. These acid/salt mixtures are also useful for suppressing appetite, preventing epileptic seizures, and treating cancer.

Abstract: A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.

Abstract: Glycine, threonine, and serine can enhance the sensitivity of bacteria to serum, plasma, or whole blood, and therefore can be used as molecules to improve the bactericidal effect of the serum, the plasma, or the whole blood.

Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.

Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.

Abstract: The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.

Abstract: The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H2O) (n?8). Days 1-28, rats received a daily 5 g/kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 ?l) were acquired for analysis of glucose and ?HB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until ?HB returned to baseline. At day 1 and 28, 10 ?L of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment.